Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
SUNNYVALE, Calif., July 24, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its second quarter ended June 30, 2013 after the NASDAQ Market closes on Wednesday, July 31, 2013. The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day.
Conference call and webcast details:
Date: July 31, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877) 303-7908
International: (678) 373-0875
Replay Number (Toll Free): (855) 859-2056
Replay Number (International): (404) 537-3406
Conference ID #: 23863642
A webcast replay will be available on the Pharmacyclics website for 30 days.
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.
Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.
SOURCE Pharmacyclics, Inc.